Balaji Amines Limited · NSE:BALAMINES

Balaji Amines — Investor Presentation (August 2021)

42 slides from Balaji Amines's investor presentation, Aug 4, 2021

  1. Slide 1: Cover letter to stock exchanges

    4th August, 2021 To' The General Manager-Department of The Manager-Listing Department, Corporate Services, National Stock Exchange of India Limited, BSE Linited, "Exchange Plaza", 5th Floor, Phiroze Jeejeebhoy Towers, Plot No. C/1, G Block, Dalal Street, Mumbai -400 001. Bandra-Kurla Complex, Scrip

  2. Slide 2: Balaji Amines Limited Investor Presentation August 2021

    Balaji Amines Limited Investor Presentation August 2021 1

  3. Slide 3: Disclaimer

    Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Balaji Amines Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti

  4. Slide 4: Q1FY22: Standalone Performance Highlights

    Q1FY22: Standalone Performance Highlights Revenue (Rs. Crore) EBITDA (Rs. Crore) PAT (Rs. Crore) Margin 25.12% 30.30% 29.66% 16.27% 21.03% 20.75% 85.12% 118.54% 136.10% 394.26 114.16 116.92 79.23 81.81 376.71 212.97 53.50 34.65 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 3

  5. Slide 5: Q1FY22: Consolidated Performance Highlights

    Q1FY22: Consolidated Performance Highlights Revenue (Rs. Crore) EBITDA (Rs. Crore) PAT (Rs. Crore) Margin 24.31% 31.73% 31.93% 14.09% 21.26% 21.55% 101.60% 164.77% 208.42% 451.94 144.29 97.40 417.63 132.52 88.81 224.19 54.50 31.58 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 4

  6. Slide 6: Q1FY22 Performance Highlights

    Q1FY22 Performance Highlights Sales volumes were up by 20.16% from 18,306 MT in Q1FY21 to 21,997 MT in Q1FY22. Our operations were not hampered much during the second wave of COVID-19 in India, as our products fall under essential category, with many of them also required as intermediates in medicat

  7. Slide 7: Expansion Plans

    Expansion Plans Acetonitrile Di-methyl Carbonate Methylamines Dimethyl Formamide ❑ Have installed capacity of 9,000 ton ❑ Under the phase-1 of Greenfield ❑ Market Leader in Methylamines ❑ Market Leader in Dimethyl production in India with installed Formamide (DMF) production in per annum (TPA). Curr

  8. Slide 8: Standalone Statement of Profit & Loss

    Standalone Statement of Profit & Loss Particulars (in Rs. Crore) Q1FY22 Q1FY21 Y-o-Y FY21 Total Revenue 394.26 212.97 85.12% 1,239.81 Raw Material 197.91 111.68 622.69 Employee expense 18.09 10.83 65.68 Other expenses 61.33 36.96 212.79 EBITDA 116.92 53.50 118.54% 338.65 EBITDA Margin 29.66% 25.12%

  9. Slide 9: Consolidated Statement of Profit & Loss

    Consolidated Statement of Profit & Loss Particulars (in Rs. Crore) Q1FY22 Q1FY21 Y-o-Y FY21 Total Revenue 451.94 224.19 101.60% 1,317.5 Raw Material 219.66 118.35 630.25 Employee expense 18.66 11.22 67.83 Other expenses 69.32 40.11 240.15 EBITDA 144.29 54.50 164.77% 379.30 EBITDA Margin 31.93% 24.31

  10. Slide 10: Section 1: About Us

    SECTION 1 About Us

  11. Slide 11: Amines Industry – Unique but Critical Industry with growth potential

    Amines Industry – Unique but Critical Industry with growth potential The size of Aliphatic Amines industry globally is For Indian Amine manufacturers, 45-55% of the $4.9 billion. Globally, the Amine industry is export revenue comes from Europe alone. USA 8 1 oligopolistic with two-three producers ca

  12. Slide 12: Balaji Amines Ltd – A Leading player in Aliphatic Amines in India

    Balaji Amines Ltd – A Leading player in Aliphatic Amines in India Largest manufacturer of Aliphatic State-of-the-art manufacturing 25+ Product basket Zero Liquid Discharge Amines in India facilities fully equipped with latest DCS technology facilities Only Company to develop an Indigenous Technology

  13. Slide 13: Our Products are supplied to India's fast-growing Industries

    Our Products are supplied to India’s fast-growing Industries INDUSTRY WISE – REVENUE BREAKUP 3% 4% 3% 4% 3% 2% 4% 51% 26% Pharma Agrochem Paints & Resins Animal Feeds Oil & Gas Rubber Cleaning Chemicals Water Treatment Chemicals Dye and Textiles Others 12

  14. Slide 14: Highly Experienced Management Team

    Highly Experienced Management Team Mr. A. Srinivas Reddy Mr. D. Ram Reddy Mr. A. Pratap Reddy Mr. N. Rajeshwar Reddy Mr. G. Hemanth Reddy Whole Time Director Managing Director Executive Chairman Joint Managing Director Whole Time Director & CFO • Post Graduate in Computer • 35 years of experience ac

  15. Slide 15: Diversified Product Portfolio

    Diversified Product Portfolio Amines Amine Derivatives Specialty & Other Chemicals • Aliphatic Amines find increasing consumption and • Amine Derivatives are used to make further salts and • Albeit a small and fastest growing segment applications in a Chemically mature Industry such other complex ch

  16. Slide 16: Clientele

    Clientele Amines Amine Derivatives Specialty & Other Chemicals 15 The company logos mentioned above are the property of their respective owners and are used here for identification purposes only

  17. Slide 17: Well positioned Business Model aimed at Sustainable growth

    Well positioned Business Model aimed at Sustainable growth Focus towards high-value derivatives and Develop new indigenous technology for specialty chemicals with an aim to move up manufacturing products leading to lowering in the value-chain with vertical integration manufacturing costs & improving

  18. Slide 18: Key Products (Current & Proposed) in Portfolio

    Key Products (Current & Proposed) in Portfolio Balaji Amines In MTPA Balaji Speciality Chemicals In MTPA Existing Installed Proposed Licensed Product Application Areas Product Application Areas Capacity Capacity Capacity Methyl Amine 48,000 50,000 Pharma, Agro, Dye & Rubber Pesticides, Ethylenediami

  19. Slide 19: We are Global suppliers – a significant validation of our Capabilities

    We are Global suppliers – a significant validation of our Capabilities 14.96% of the Total Revenue for FY21 i.e. Rs. 185.44 Crore is generated from exports spanning across continents 18 Note: Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representati

  20. Slide 20: Awards & Certificates (1/2)

    Awards & Certificates – A Testimony of our capabilities (1/2) ISO Certificate Two Star Export House ISO Certificate ISO 9001 : 2015 Certificate Certificate of Merit – CHEMEXCIL First Award – CHEMEXCIL 19

  21. Slide 21: Awards & Certificates (2/2)

    Awards & Certificates – A Testimony of our capabilities (2/2) Product Innovator of Distinguished Contribution Excellent CSR in Water the Year in Chemicals – in the Indian Chemicals Conservation 2018 Industry WHO GMP Certificate REACH Pre-Registration Niryat Shree Award by FIEO 20

  22. Slide 22: We are Growing…Sustainably and Consistently

    We are Growing…Sustainably and Consistently “Long-Term Issuer Rating affirmed at ‘IND AA-’ by India Ratings and Research (Ind-Ra) .” The ratings process highlighted the following factors:- • Largest manufacturer of aliphatic amines and their derivatives in India • Increased product offtake and meani

  23. Slide 23: High entry barrier Business – Paving way for Sustainable growth

    High entry barrier Business – Paving way for Sustainable growth Complex Manufacturing High Lead time Capex Heavy Business Complex manufacturing process Niche product offering with high High fixed costs, with fixed asset requiring high levels of lead time in customer approvals turns hovering in the r

  24. Slide 24: Well positioned Business Model aimed at Sustainable growth

    Well positioned Business Model aimed at Sustainable growth Value-Added Products Applicability in Solvents segment Capex towards high-value derivatives and specialty Solvents account for 80%-90% of the mass chemicals will materialize into higher revenue and enhanced margins 01 utilised in a typical p

  25. Slide 25: Greenfield Project to fuel growth and add Revenue Visibility

    Greenfield Project to fuel growth and add Revenue Visibility Strategically Mega Project Project Capex Product Profile Indigenous New Products = 1st High Demand Located Plant Status Technology mover advantage for Products Environmental Ethylamines plant in Project cost of Rs. Capacity installed Plan

  26. Slide 26: Balaji Speciality Chemicals – Production commenced in FY20

    Balaji Speciality Chemicals – Production commenced in FY20 Manufacturing products such Undertook capex of about Rs. Received Mega project status as Ethylene Diamine, 250 crore; loan contribution of for the Project from 01 Piperazine, 02 Rs. 150 crore. Expected 03 Maharashtra State Aminoethylpiperazi

  27. Slide 27: R&D led Investments to provide significant early mover advantage

    R&D led Investments to provide significant early mover advantage Environment Conscious New Products Identification of new products and Waste-water treatment and minimization of effluents development of latest process by adopting Industry best practices for effluent technologies treatment. Efficiency

  28. Slide 28: Section 2: Hotel Division

    SECTION 2 Hotel Division

  29. Slide 29: Balaji Sarovar Premiere (Solapur)

    Balaji Sarovar Premiere – Best in class Business Hotel in Solapur Balaji Sarovar Premiere (Solapur) 28

  30. Slide 30: Balaji Sarovar Premiere – At a Glance

    Balaji Sarovar Premiere – At a Glance • Commenced Operations in October 2013 Hotel Balaji Sarovar Premier is the only 5 star hotel in Solapur • Invested Rs. 110 crore in the Hotel Project via mix of Debt and Equity • Tied up with Sarovar Group for the Management of the Hotel on Management Fee + Reve

  31. Slide 31: Balaji Sarovar Premiere – Operating Matrix (FY21)

    Balaji Sarovar Premiere – Operating Matrix (FY21) 129 Rooms Constitutes 0.59% Rs. 3,634 ARR of Total Revenue 23% Occupancy Rate Balaji Negligible Routine Capex incurred Sarovar RS. 830 RevPAR Premiere Renowned Five Star Hotel In the City of Solapur ARR : Average Room Revenue RevPAR: Revenue per Avai

  32. Slide 32: Section 3: Financial Performance

    SECTION 3 Financial Performance

  33. Slide 33: Consolidated Performance Highlights

    Consolidated Performance Highlights Revenue (Rs. Crs.) EBITDA (Rs. Crs.) PAT (Rs. Crs.) +18% 1,318 379 244 +26% +31% 943 941 861 670 190 193 186 113 117 153 97 82 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 EBITDA Margin (%) PAT Margin (%) RoE (%) 28.8% 18.5% 27.0% 22.

  34. Slide 34: Strong Core RoCE Profile

    Strong Core RoCE Profile Particulars (Rs. Crs.) FY20 FY21 Consolidated Debt 259.57 127.07 909.92 ▪ For FY20, investments made to the tune of Rs. 112.35 crore in Consolidated Networth 668.37 subsidiary company of Balaji Amines not considered, as the Total Capital Employed 927.94 1,036.99 volume offta

  35. Slide 35: Standalone Statement of Profit & Loss

    Standalone Statement of Profit & Loss Particulars (in Rs. Crore) FY21 FY20 YoY Total Revenue 1,239.81 929.32 33.41% Raw Material 622.69 511.17 Employee Cost 65.68 49.62 Other Expenses 212.79 178.50 EBITDA 338.65 190.03 78.21% EBITDA Margin 27.31% 20.45% Depreciation 23.34 24.18 EBIT 315.31 165.85 90

  36. Slide 36: Standalone Balance Sheet Statement

    Standalone Balance Sheet Statement ASSETS (Rs. Crs.) Mar-21 Mar-20 EQUITY AND LIABILITIES (Rs. Crs.) Mar-21 Mar-20 (1) NON-CURRENT ASSETS EQUITY (a) Property, plant & equipment 344.34 363.40 (a) Equity Share capital 6.48 6.48 (b) Capital work-in-progress 173.27 46.27 (b) Other equity 890.93 661.16 S

  37. Slide 37: Consolidated Profit & Loss Account

    Consolidated Profit & Loss Account Particulars (in Rs. Crore) FY21 FY20 YoY Total Revenue 1,317.53 940.79 40.05% Raw Material 630.26 513.83 Employee Cost 67.82 50.99 Other Expenses 240.15 190.21 EBITDA 379.30 185.76 104.19% EBITDA Margin 28.79% 19.75% Depreciation 34.41 31.62 EBIT 344.89 154.14 123.

  38. Slide 38: Consolidated Balance Sheet Statement

    Consolidated Balance Sheet Statement ASSETS (Rs. Crore) Mar-21 Mar-20 EQUITY AND LIABILITIES (Rs. Crore) Mar-21 Mar-20 (1) NON-CURRENT ASSETS EQUITY (a) Property, plant & equipment 542.92 573.00 (a) Equity Share capital 6.48 6.48 (b) Capital work-in-progress 173.28 46.26 (b) Other equity 887.91 651.

  39. Slide 39: Consistent Dividend Payout

    Consistent Dividend Payout 200% 160% 140% 130% 110% FY17 FY18 FY19 FY20 FY21 Particulars (Rs. per share) FY17 FY18 FY19 FY20 FY21 Consolidated Book Value 111.87 149.71 182.71 206.28 280.84 Consolidated EPS 25.42 34.93 36.27 32.34 73.52 Dividend 2.20 2.60 2.80 3.20 4.00 38

  40. Slide 40: Section 4: Moving towards Growth Prospects

    SECTION 4 Moving towards Growth Prospects

  41. Slide 41: Balaji Amines Ltd - Progressing steadily

    Balaji Amines Ltd - Progressing steadily Capex Phase Brownfield Expansion Subsidiary Expansion Greenfield Manufacturing of new products such Expansion and commercialization of Capex for Phase 1 of Greenfield Moving to higher margin niche as Ethylene Diamine, Piperazine and 90-acre project in MIDC Ch

  42. Slide 42: For further information, please contact

    For further information, please contact: Company : Investor Relations Advisors : Strategic Growth Advisors Pvt. Ltd. Balaji Amines Ltd. CIN - U74140MH2010PTC204285 CIN - L24132MH1988PLC049387 Mr. Shogun Jain / Mr. Parin Narichania Email - info@balajiamines.com shogun.jain@sgapl.net / parin.n@sgapl.n

Balaji Amines — Investor Presentation (August 2021) on 6ix